Sara M. Tolaney, MD, MPH, discusses the real-world efficacy of fam-trastuzumab deruxtecan in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.
Shay Elkins, a patient with triple negative breast cancer, shares her experience of relapse six months post-treatment, eventually leading her to seek a second opinion for her recurring symptoms. Dr. Noor Abuhadra discusses second-line treatment options for metastatic triple negative breast cancer, emphasizing newer therapies like antibody drug conjugates and PARP inhibitors, and highlights the evolving landscape that offers hope for patients.
Nuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.
Treatment with trastuzumab deruxtecan resulted in lower exposure-adjusted incidence rates per patient-year of treatment-emergent adverse effects compared with treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer, according to safety analysis from the phase 3 DESTINY-Breast04 trial.